trial · primary record
M-CENK, Suspension for Infusion, Cryopreserved (M-CENK) (Cohort 2 part B)
Metastatic Solid Tumor
| Phase | Phase 1 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 50 |
| Primary completion | 2027-05-31 |
| Primary endpoint | Primary Objective (cohort 1 and cohort 2, part A subjects): Determine the safety of mononuclear cell (MNC) apheresis collection by the number of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) related to apheresis. |
| Registry ID | NCT04898543 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:42:37.413Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04898543
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.